Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Journal of Clinical Pharmacology|January 27, 2009
Challenges in the clinical development requirements for the marketing authorization of new medicines in southeast AsiaAlex KudrinHuman Vaccines & Immunotherapeutics|August 17, 2012
Reimbursement challenges with cancer immunotherapeuticsAlex KudrinHuman Vaccines & Immunotherapeutics|December 9, 2014
Cancer vaccines: what do we need to measure in clinical trials?Alex KudrinHuman Vaccines & Immunotherapeutics|August 17, 2012
Business models and opportunities for cancer vaccine developersAlex KudrinHuman Vaccines & Immunotherapeutics|August 17, 2012
Overview of cancer vaccines: considerations for developmentAlex KudrinImmunology and Cell Biology|November 28, 2007
Cunning factor: macrophage migration inhibitory factor as a redox-regulated targetAlex Kudrin, David RayImmunotherapy|February 26, 2015
Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseasesJürgen Braun, Alex KudrinBiologicals : Journal of the International Association of Biological Standardization|April 28, 2016
Switching to biosimilar infliximab (CT-P13): Evidence of clinical safety, effectiveness and impact on public healthJürgen Braun, Alex KudrinHuman Vaccines & Immunotherapeutics|August 3, 2012
Overview of the cancer vaccine field: are we moving forward?Alex Kudrin, Michael G HannaBiologicals : Journal of the International Association of Biological Standardization|December 4, 2014
Case studies on clinical evaluation of biosimilar monoclonal antibody: scientific considerations for regulatory approvalAlex Kudrin, Ivana Knezevic, Jeewon Joung, et al.Pageof 2